

# Thomas S Harrison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8913642/publications.pdf>

Version: 2024-02-01

175  
papers

15,191  
citations

28736

57  
h-index

22488

117  
g-index

183  
all docs

183  
docs citations

183  
times ranked

9844  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2010, 50, 291-322.	2.9	2,195
2	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	2.9	1,429
3	Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. <i>Lancet</i> , The, 2004, 363, 1764-1767.	6.3	432
4	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. <i>New England Journal of Medicine</i> , 2014, 371, 1599-1608.	13.9	383
5	Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy. <i>Nature Reviews Neurology</i> , 2017, 13, 13-24.	4.9	344
6	Fungal infections in HIV/AIDS. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e334-e343.	4.6	327
7	Tackling the emerging threat of antifungal resistance to human health. <i>Nature Reviews Microbiology</i> , 2022, 20, 557-571.	13.6	311
8	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. <i>Clinical Infectious Diseases</i> , 2014, 58, 736-745.	2.9	299
9	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. <i>New England Journal of Medicine</i> , 2018, 378, 1004-1017.	13.9	296
10	Cryptococcal meningitis. <i>British Medical Bulletin</i> , 2004, 72, 99-118.	2.7	286
11	Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa. <i>Clinical Infectious Diseases</i> , 2009, 48, 856-862.	2.9	283
12	The Case for Adopting the "Species Complex" Nomenclature for the Etiologic Agents of Cryptococcosis. <i>MSphere</i> , 2017, 2, .	1.3	274
13	Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine From Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2011, 53, 1019-1023.	2.9	266
14	Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole. <i>Clinical Infectious Diseases</i> , 2007, 45, 76-80.	2.9	261
15	High-Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV-Infected Patients: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 123-130.	2.9	238
16	Adjunctive interferon- $\gamma$ immunotherapy for the treatment of HIV-associated cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1105-1113.	1.0	238
17	Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. <i>BMC Infectious Diseases</i> , 2010, 10, 67.	1.3	222
18	<i>Cryptococcus neoformans</i> Resides in an Acidic Phagolysosome of Human Macrophages. <i>Infection and Immunity</i> , 1999, 67, 885-890.	1.0	214

#	ARTICLE	IF	CITATIONS
19	HIV-associated cryptococcal meningitis. <i>Aids</i> , 2007, 21, 2119-2129.	1.0	213
20	Symptomatic Relapse of HIV-Associated Cryptococcal Meningitis after Initial Fluconazole Monotherapy: The Role of Fluconazole Resistance and Immune Reconstitution. <i>Clinical Infectious Diseases</i> , 2006, 43, 1069-1073.	2.9	210
21	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 702-709.	2.9	201
22	Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. <i>Lancet</i> , The, 2015, 385, 2173-2182.	6.3	197
23	Dose Response Effect of High-Dose Fluconazole for HIV-Associated Cryptococcal Meningitis in Southwestern Uganda. <i>Clinical Infectious Diseases</i> , 2008, 47, 1556-1561.	2.9	180
24	Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. <i>Aids</i> , 2009, 23, 701-706.	1.0	168
25	Combination Flucytosine and High-Dose Fluconazole Compared with Fluconazole Monotherapy for the Treatment of Cryptococcal Meningitis: A Randomized Trial in Malawi. <i>Clinical Infectious Diseases</i> , 2010, 50, 338-344.	2.9	166
26	Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis: A Prospective Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 130-134.	0.9	162
27	Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 629-637.	4.6	151
28	IFN- $\gamma$ at the Site of Infection Determines Rate of Clearance of Infection in Cryptococcal Meningitis. <i>Journal of Immunology</i> , 2005, 174, 1746-1750.	0.4	150
29	The <i>Cryptococcus neoformans</i> Titan cell is an inducible and regulated morphotype underlying pathogenesis. <i>PLoS Pathogens</i> , 2018, 14, e1006978.	2.1	137
30	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2000-2008.	3.9	130
31	Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2012, 54, 121-128.	2.9	127
32	Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2435-2444.	1.3	121
33	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. <i>New England Journal of Medicine</i> , 2022, 386, 1109-1120.	13.9	119
34	Cerebrospinal Fluid Cytokine Profiles Predict Risk of Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis. <i>PLoS Pathogens</i> , 2015, 11, e1004754.	2.1	117
35	Chloroquine induces human mononuclear phagocytes to inhibit and kill <i>Cryptococcus neoformans</i> by a mechanism independent of iron deprivation.. <i>Journal of Clinical Investigation</i> , 1997, 100, 1640-1646.	3.9	116
36	The Phenotype of the <i>Cryptococcus</i> -Specific CD4+ Memory T-Cell Response Is Associated With Disease Severity and Outcome in HIV-Associated Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2013, 207, 1817-1828.	1.9	113

#	ARTICLE	IF	CITATIONS
37	Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa. <i>PLoS ONE</i> , 2013, 8, e69288.	1.1	112
38	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 999-1014.	3.9	112
39	Tracing Genetic Exchange and Biogeography of <i>Cryptococcus neoformans</i> var. <i>grubii</i> at the Global Population Level. <i>Genetics</i> , 2017, 207, 327-346.	1.2	105
40	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7224-7231.	1.4	99
41	Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 581-587.	2.9	99
42	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003847.	1.3	94
43	Advances in the diagnosis and treatment of fungal infections of the CNS. <i>Lancet Neurology</i> , The, 2018, 17, 362-372.	4.9	93
44	<i>Cryptococcus neoformans</i> Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2014, 209, 74-82.	1.9	90
45	Clinical Application of Whole-Genome Sequencing To Inform Treatment for Multidrug-Resistant Tuberculosis Cases. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1473-1483.	1.8	89
46	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. <i>Aids</i> , 2009, 23, 1182-1183.	1.0	83
47	Pulmonary Cryptococcosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 141-150.	0.8	81
48	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1815-1820.	1.3	80
49	A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. <i>G3: Genes, Genomes, Genetics</i> , 2017, 7, 1165-1176.	0.8	79
50	High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 686-692.	2.9	76
51	Association of Mannose-Binding Lectin Deficiency with Acute Invasive Aspergillosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1486-1491.	2.9	75
52	Low Diversity <i>Cryptococcus neoformans</i> Variety <i>grubii</i> Multilocus Sequence Types from Thailand Are Consistent with an Ancestral African Origin. <i>PLoS Pathogens</i> , 2011, 7, e1001343.	2.1	74
53	A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1363-1370.	1.0	73
54	Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. <i>Journal of Infection</i> , 2012, 64, 76-81.	1.7	69

#	ARTICLE	IF	CITATIONS
55	Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. <i>Aids</i> , 2010, 24, 405-410.	1.0	64
56	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e143-e147.	4.6	63
57	Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus-associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 393-401.	2.9	62
58	A Prospective Longitudinal Study of the Clinical Outcomes from Cryptococcal Meningitis following Treatment Induction with 800 mg Oral Fluconazole in Blantyre, Malawi. <i>PLoS ONE</i> , 2013, 8, e67311.	1.1	62
59	Cryptococcal immune reconstitution inflammatory syndrome. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 26-34.	1.3	60
60	Baseline Correlation and Comparative Kinetics of Cerebrospinal Fluid Colony-Forming Unit Counts and Antigen Titers in Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2005, 192, 681-684.	1.9	59
61	Genomic epidemiology of <i>Cryptococcus</i> yeasts identifies adaptation to environmental niches underpinning infection across an African HIV/AIDS cohort. <i>Molecular Ecology</i> , 2017, 26, 1991-2005.	2.0	59
62	Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 530-531.	4.6	57
63	Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1038-1042.	1.4	57
64	Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. <i>Journal of Infection</i> , 2005, 51, e221-e224.	1.7	56
65	A Prospective Study of Mortality from Cryptococcal Meningitis following Treatment Induction with 1200mg Oral Fluconazole in Blantyre, Malawi. <i>PLoS ONE</i> , 2014, 9, e110285.	1.1	56
66	Long term mortality and disability in Cryptococcal Meningitis: a systematic literature review.. <i>Clinical Infectious Diseases</i> , 2018, 66, 1122-1132.	2.9	53
67	Cryptococcal Antigen Screening and Preemptive Therapy in Patients Initiating Antiretroviral Therapy in Resource-Limited Settings. <i>Journal of the International Association of Providers of AIDS Care</i> , 2012, 11, 374-379.	1.2	52
68	Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2793-2800.	1.4	52
69	Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living With Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies. <i>Clinical Infectious Diseases</i> , 2021, 72, 1268-1278.	2.9	51
70	Managing cryptococcosis in the immunocompromised host. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 596-603.	1.3	47
71	Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 2013, 208, 351-361.	1.9	47
72	Cryptococcal meningitis: A neglected NTD?. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005575.	1.3	47

#	ARTICLE	IF	CITATIONS
73	Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Na <sup>+</sup> ve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS Test. <i>Frontiers in Microbiology</i> , 2018, 9, 409.	1.5	46
74	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019, 10, .	1.8	44
75	Outcomes of cryptococcal meningitis in antiretroviral na <sup>+</sup> ve and experienced patients in South Africa. <i>Journal of Infection</i> , 2010, 60, 496-498.	1.7	42
76	A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 832-838.	0.6	41
77	AMBIsome Therapy Induction Optimisation (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> , 2018, 19, 649.	0.7	41
78	Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: The role of inadequate secondary prophylaxis. <i>South African Medical Journal</i> , 2010, 100, 378.	0.2	40
79	Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis. <i>Journal of Infection</i> , 2015, 70, 668-675.	1.7	39
80	Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus <sup>+</sup> infected Adults With CD4 Cell Counts $\leq 100/\mu\text{L}$ : A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2019, 68, 688-698.	2.9	38
81	Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. <i>Clinical Infectious Diseases</i> , 2020, 70, 1683-1690.	2.9	38
82	Immune dysfunction in HIV-seronegative, <i>Cryptococcus gattii</i> meningitis. <i>Journal of Infection</i> , 2007, 54, e165-e168.	1.7	37
83	Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	37
84	Cryptococcal Antigen Screening for Patients Initiating Antiretroviral Therapy: Time for Action. <i>Clinical Infectious Diseases</i> , 2010, 51, 1463-1465.	2.9	35
85	Dengue Hemorrhagic Fever with Fulminant Hepatic Failure in an Immigrant Returning to Bangladesh. <i>Clinical Infectious Diseases</i> , 2003, 37, e1-e4.	2.9	33
86	Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 1030.	0.3	33
87	Intrathecal Production and Secretion of Vascular Endothelial Growth Factor during Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2004, 190, 1310-1317.	1.9	32
88	Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifampentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4471-4473.	1.4	30
89	<i>Cryptococcus neoformans</i> and Cryptococcosis. <i>Journal of Infection</i> , 2000, 41, 12-17.	1.7	29
90	Role of Capsule and Interleukin-6 in Long-Term Immune Control of <i>Cryptococcus neoformans</i> Infection by Specifically Activated Human Peripheral Blood Mononuclear Cells. <i>Infection and Immunity</i> , 2006, 74, 5302-5310.	1.0	28

#	ARTICLE	IF	CITATIONS
91	Pulmonary cryptococcosis misdiagnosed as smear-negative pulmonary tuberculosis with fatal consequences. <i>International Journal of Infectious Diseases</i> , 2010, 14, e310-e312.	1.5	28
92	XDR-TB transmission in London: Case management and contact tracing investigation assisted by early whole genome sequencing. <i>Journal of Infection</i> , 2016, 73, 210-218.	1.7	28
93	The burden of HIV-associated cryptococcal disease. <i>Aids</i> , 2009, 23, 531-532.	1.0	27
94	The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. <i>Journal of Infection</i> , 2013, 66, 75-79.	1.7	27
95	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	27
96	Immunotherapy for fungal infections. <i>Current Opinion in Microbiology</i> , 2012, 15, 434-439.	2.3	26
97	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	25
98	Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. <i>Aids</i> , 2010, 24, 1233-1235.	1.0	24
99	Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?. <i>Aids</i> , 2010, 24, 612-614.	1.0	23
100	Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days. <i>MBio</i> , 2014, 5, e00725-13.	1.8	23
101	AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 276.	0.7	22
102	Correspondence of In Vitro and In Vivo Fluconazole Dose-Response Curves for <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3297-3301.	1.4	21
103	The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies. <i>PLoS ONE</i> , 2017, 12, e0171917.	1.1	21
104	Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts - time to implement in South Africa?. <i>South African Medical Journal</i> , 2011, 101, 232.	0.2	20
105	Early Clinical and Subclinical Visual Evoked Potential and Humphrey's Visual Field Defects in Cryptococcal Meningitis. <i>PLoS ONE</i> , 2012, 7, e52895.	1.1	20
106	Brief Report: Point of Care Cryptococcal Antigen Screening: Pipetting Finger-Prick Blood Improves Performance of Immunomycologics Lateral Flow Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 574-578.	0.9	19
107	Evaluation of a Novel Semiquantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	19
108	Immune correlates of HIV-associated cryptococcal meningitis. <i>PLoS Pathogens</i> , 2017, 13, e1006207.	2.1	19

#	ARTICLE	IF	CITATIONS
109	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. <i>Clinical Infectious Diseases</i> , 2019, 69, 588-595.	2.9	18
110	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 16-18.	4.6	18
111	Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 724-731.	1.3	17
112	A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
113	Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. <i>Journal of Infection</i> , 2011, 63, 484-486.	1.7	15
114	Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008â€“2014. <i>Journal of Infection</i> , 2017, 74, 260-271.	1.7	15
115	Forgotten but not gone: HIV-associated cryptococcal meningitis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 756-758.	4.6	14
116	Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report. <i>BMC Infectious Diseases</i> , 2018, 18, 520.	1.3	14
117	One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi. <i>Clinical Infectious Diseases</i> , 2020, 70, 521-524.	2.9	13
118	Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 26-29.	2.9	13
119	Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1365-1373.	4.6	13
120	Presentations and outcomes of central nervous system TB in a UK cohort: The high burden of neurological morbidity. <i>Journal of Infection</i> , 2021, 82, 90-97.	1.7	12
121	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa489.	0.4	12
122	Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 199-202.	0.6	11
123	Recent advances in managing HIV-associated cryptococcal meningitis. <i>F1000Research</i> , 2019, 8, 743.	0.8	11
124	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 493-500.	2.9	10
125	Diagnostic Accuracy of the Biosynex CryptoPS Cryptococcal Antigen Semiquantitative Lateral Flow Assay in Patients with Advanced HIV Disease. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	1.8	10
126	Time to embrace access programmes for medicines: lessons from the South African flucytosine access programme. <i>International Journal of Infectious Diseases</i> , 2020, 95, 459-461.	1.5	10



#	ARTICLE	IF	CITATIONS
127	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. <i>Aids</i> , 2020, 34, 1425-1428.	1.0	9
128	Short-term Mortality Outcomes of HIV-Associated Cryptococcal Meningitis in Antiretroviral Therapy-naïve and Experienced Patients in Sub-Saharan Africa. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab397.	0.4	9
129	Establishing targets for advanced HIV disease: A call to action. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1266.	0.3	9
130	Understanding Causal Pathways in Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2019, 219, 344-346.	1.9	8
131	Equity in clinical trials for HIV-associated cryptococcal meningitis: A systematic review of global representation and inclusion of patients and researchers. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009376.	1.3	8
132	Should Antiretroviral Therapy Be Delayed for 10 Weeks for Patients Treated with Fluconazole for Cryptococcal Meningitis?. <i>Clinical Infectious Diseases</i> , 2010, 51, 986-987.	2.9	7
133	Cryptococcal meningitis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2017, 78, C125-C127.	0.2	7
134	Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1652-1657.	2.9	7
135	The Lived Experience Of Participants in an African Randomised trial (LEOPARD): protocol for an in-depth qualitative study within a multisite randomised controlled trial for HIV-associated cryptococcal meningitis. <i>BMJ Open</i> , 2021, 11, e039191.	0.8	7
136	Cryptococcal antigen screening in HIV-infected adults - let's get straight to the point-of-care. <i>Aids</i> , 2015, 30, 1.	1.0	7
137	Cryptococcal meningitis in apparently immunocompetent patients: association with idiopathic CD4+ lymphopenia. <i>Practical Neurology</i> , 2018, 18, 166-169.	0.5	6
138	AMBIsome Therapy Induction Optimisation (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. <i>BMJ Open</i> , 2019, 9, e026288.	0.8	6
139	Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1584-1586.	1.1	6
140	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab066.	0.4	6
141	Amphotericin B plus Fluconazole for HIV-associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1784-1786.	2.9	5
142	Positive predictive value of the UK clinical case definition for H1N1/09 (swine) influenza. <i>Journal of Infection</i> , 2010, 60, 405-407.	1.7	5
143	Cerebrospinal Fluid HIV-1 Viral Load During Treatment of Cryptococcal Meningitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 668-669.	0.9	5
144	Systemic fungal infections. <i>Medicine</i> , 2014, 42, 26-30.	0.2	5

#	ARTICLE	IF	CITATIONS
145	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. <i>MBio</i> , 2018, 9, .	1.8	5
146	Decision making in a clinical trial for a life-threatening illness: Therapeutic expectation, not misconception. <i>Social Science and Medicine</i> , 2022, 305, 115082.	1.8	5
147	Access to antifungal medicines in resource-poor countries – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 371.	4.6	4
148	The treatment of a pregnant HIV positive patient with cryptococcal meningitis in Malawi. Case report and review of treatment options. <i>Medical Mycology Case Reports</i> , 2018, 19, 9-12.	0.7	4
149	Effect of oral fluconazole 1200mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis. <i>Aids</i> , 2018, 32, 2259-2261.	1.0	4
150	Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana. <i>Medicine (United States)</i> , 2020, 99, e22606.	0.4	4
151	Reducing Mortality Associated with Opportunistic Infections among Patients with Advanced HIV Infection in Sub-Saharan Africa: Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009, 49, 812-813.	2.9	3
152	Prevention of AIDS-associated cryptococcosis in resource-poor areas. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 892-894.	4.6	3
153	Poor specificity of urinary cryptococcal antigen testing. <i>HIV Medicine</i> , 2018, 19, e47-e48.	1.0	3
154	Determine TB-LAM point-of-care tuberculosis assay predicts poor outcomes in outpatients during their first year of antiretroviral therapy in South Africa. <i>BMC Infectious Diseases</i> , 2020, 20, 555.	1.3	3
155	Cryptococcosis in Asia. , 0, , 287-297.		3
156	Combination Therapy for HIV-Associated Cryptococcal Meningitis – A Success Story. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 1098.	1.5	3
157	Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana. <i>Biomedicines</i> , 2022, 10, 1399.	1.4	3
158	Systemic fungal infections. <i>Medicine</i> , 2005, 33, 116-119.	0.2	2
159	Reply to Pasqualotto. <i>Clinical Infectious Diseases</i> , 2008, 47, 1110-1111.	2.9	2
160	Evaluation of a pro-active strategy for managing tuberculosis – HIV co-infection in a UK tertiary care setting. <i>International Journal of STD and AIDS</i> , 2013, 24, 263-268.	0.5	2
161	Reply to Rajasingham and Boulware. <i>Clinical Infectious Diseases</i> , 2019, 69, 732-735.	2.9	2
162	HIV-1C env and gag Variation in the Cerebrospinal Fluid and Plasma of Patients with HIV-Associated Cryptococcal Meningitis in Botswana. <i>Viruses</i> , 2020, 12, 1404.	1.5	2

#	ARTICLE	IF	CITATIONS
163	Rapid urine-based screening tests increase the yield of same-day tuberculosis diagnoses among patients living with advanced HIV disease. <i>Aids</i> , 2022, Publish Ahead of Print, .	1.0	2
164	Prior Pulmonary Tuberculosis Is a Risk Factor for Asymptomatic Cryptococcal Antigenemia in a Cohort of Adults With Advanced Human Immunodeficiency Virus Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
165	Systemic fungal infections. <i>Medicine</i> , 2009, 37, 660-664.	0.2	1
166	Vitamin D deficiency in HIV-infected South Africans: Common, and not associated with susceptibility, immune response, or outcome in HIV-associated cryptococcal meningitis. <i>International Journal of Infectious Diseases</i> , 2014, 21, 284.	1.5	1
167	Itraconazole and antiretroviral therapy: strategies for empirical dosing – Author's reply. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1123-1124.	4.6	1
168	Low-cerebrospinal fluid white cell counts and mortality in HIV-associated pneumococcal meningitis. <i>Aids</i> , 2019, 33, 1539-1541.	1.0	1
169	Neurological deterioration in a patient with HIV-associated cryptococcal meningitis initially improving on antifungal treatment: a case report of coincidental racemose neurocysticercosis. <i>BMC Infectious Diseases</i> , 2021, 21, 724.	1.3	1
170	Management of Cryptococcal Meningoencephalitis in Both Developed and Developing Countries. , 0, , 565-584.		1
171	<i>Cryptococcus: Spectrum of Disease and Treatment.</i> , 2010, , 145-165.		0
172	Reply to Lee and Newton. <i>Clinical Infectious Diseases</i> , 2012, 55, 1745-1746.	2.9	0
173	Co-prevalent infections in adults with HIV-associated cryptococcal meningitis are associated with an increased risk of death: a nested analysis of the Advancing Cryptococcal meningitis Treatment for Africa (ACTA) cohort. <i>Wellcome Open Research</i> , 0, 6, 19.	0.9	0
174	Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study. <i>Wellcome Open Research</i> , 0, 4, 83.	0.9	0
175	Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study. <i>Wellcome Open Research</i> , 0, 4, 83.	0.9	0